Scleroderma doesn’t follow a single, numbered staging system the way many cancers do. Instead, it progresses through recognizable phases of skin involvement (swelling, hardening, then thinning) while internal organs can develop problems on their own timeline. Understanding these phases, and how the two main types of the disease differ, gives you a clearer picture of what to expect and what to watch for.
The Three Phases of Skin Disease
Skin changes in scleroderma move through three broadly defined phases: edematous (swelling), fibrotic (hardening), and atrophic (thinning). Not every patient moves through all three at the same pace, and some areas of the body may be in different phases at the same time.
In the edematous phase, the fingers, hands, and sometimes the face become puffy and swollen. The skin feels tight but is still soft to the touch. This phase is often the first visible sign that something beyond Raynaud’s phenomenon is happening. It can last weeks to months.
The fibrotic (indurative) phase is when the skin thickens and hardens. It becomes difficult to pinch or fold between two fingers, and fine wrinkles disappear. This is the hallmark change most people associate with scleroderma. Doctors track this phase using a tool called the modified Rodnan skin score, which rates skin thickness from 0 (normal) to 3 (severe, impossible to fold) across 17 areas of the body. A rising score signals the disease is actively progressing.
In the atrophic phase, the thickened skin gradually softens and thins, sometimes becoming fragile. This can look like improvement on the surface, but it doesn’t necessarily mean the underlying disease has stopped. Internal organ involvement may continue regardless of what the skin is doing.
Early Signs Before Skin Hardening Begins
Before the skin phases become obvious, most people experience a prodromal period dominated by two symptoms: Raynaud’s phenomenon and puffy fingers. Raynaud’s causes the fingers to turn white or blue in response to cold or emotional stress, then flush red as blood flow returns. The fingers may also feel stiff and swollen, particularly in the morning. These symptoms can precede noticeable skin thickening by months or even years, and they’re often the reason people first seek medical attention.
Tiny blood vessels near the surface of the nail beds also change early. Doctors can spot these changes with a simple magnified exam of the fingernails, and abnormal nailfold capillaries are one of the criteria used to classify the disease.
Limited vs. Diffuse: Two Different Trajectories
The disease is broadly divided into limited cutaneous and diffuse cutaneous forms, and they progress quite differently.
Limited cutaneous scleroderma confines skin thickening mostly to the hands, forearms, and face. It tends to progress more slowly, and Raynaud’s phenomenon often appears years before other symptoms. The major late complication to watch for is pulmonary arterial hypertension, a type of high blood pressure in the lungs that can develop years into the disease.
Diffuse cutaneous scleroderma spreads skin thickening to the trunk and upper arms, often within months of the first symptoms. It carries a higher risk of internal organ problems early on. About 72% of diffuse patients experience some form of disease progression, compared to 47% of limited patients. It’s also worth noting that roughly 17% of people initially diagnosed with the limited form eventually progress to the diffuse form, most commonly within the first five years.
When Internal Organs Get Involved
Organ involvement doesn’t wait for skin changes to finish. In fact, 37% of patients already have some internal organ involvement at the time they’re first diagnosed. In diffuse scleroderma specifically, up to 70% of patients develop organ complications within the first three years.
Lungs
The lungs are the most commonly affected internal organ. Interstitial lung disease, a form of scarring in the lung tissue, tends to appear early and is more common in people with the diffuse form. Pulmonary arterial hypertension, which affects the blood vessels in the lungs rather than the tissue itself, is diagnosed within five years of disease onset in about half of those who develop it. It’s more closely linked to the limited form. Both conditions are screened for regularly because treatments work better when started early.
Digestive System
Gastrointestinal problems are remarkably common. Esophageal involvement affects roughly 90% of scleroderma patients, causing heartburn, difficulty swallowing, and acid reflux as the muscles of the esophagus lose their ability to move food efficiently. Further down the digestive tract, 40% to 70% of patients develop intestinal problems. The small bowel slows down, which allows bacteria to overgrow in places they normally wouldn’t. This bacterial overgrowth leads to bloating, diarrhea, and, over time, difficulty absorbing nutrients. Malnutrition from this process is a serious long-term concern.
Kidneys
Scleroderma renal crisis is one of the most dangerous complications, though it’s less common than lung or gut involvement. It occurs in roughly 5% to 10% of all scleroderma patients, with the vast majority of cases happening in the diffuse form (10% to 25% of diffuse patients versus only 1% to 2% of limited patients). The timing is notable: 75% of renal crises develop within the first four years of diagnosis, with a median onset of just eight months. It causes a sudden spike in blood pressure and rapid kidney damage, so early monitoring is critical.
How Doctors Track Progression
Because scleroderma doesn’t have neat numbered stages, doctors rely on a combination of tools to assess where you are in the disease. The modified Rodnan skin score tracks skin thickening over time. Lung function tests and CT scans monitor for interstitial lung disease. Echocardiograms and specialized screening algorithms help detect pulmonary hypertension before symptoms become severe. Blood tests for specific antibodies also provide clues: certain antibodies are associated with lung scarring, while others point toward a higher risk of pulmonary hypertension.
The 2013 classification criteria use a point-based system that weighs features like skin thickening of the fingers, fingertip lesions, abnormal nail-fold capillaries, Raynaud’s phenomenon, lung involvement, and specific autoantibodies. A score of 9 or higher out of a possible 19 points classifies a person as having systemic sclerosis. If skin thickening extends past the knuckles on both hands, that single finding alone is enough for classification.
Long-Term Outlook by Type
Overall five-year survival for scleroderma patients is about 87%, and ten-year survival is around 78%. When broken down by type, the numbers are closer than many people expect: five-year survival is 85.5% for diffuse and 86.6% for limited. The gap widens over longer periods. At ten years, diffuse drops to 69.7% while limited holds at 78.6%. At fifteen years, diffuse survival is 54.9% and limited is 59.7%.
These numbers reflect the disease broadly and include patients diagnosed across all ages and severity levels. Individual outlook depends heavily on which organs are involved, how early treatment begins, and how the disease responds to therapy. Lung disease and pulmonary hypertension are the leading drivers of mortality, which is why aggressive screening for both has become standard practice.